Clinical Trials Logo

Clinical Trial Summary

This study will test whether a tailored, online educational intervention increases HPV vaccine uptake and intent among female college students.


Clinical Trial Description

MeFirst is the first web-based, online, educational tool designed to promote Human Papillomavirus (HPV) vaccine awareness and understanding in an effort to improve HPV vaccine intent and uptake among female university students. HPV is the most common sexually transmitted infection and causes genital warts and cancer. The HPV vaccine has been recommended for girls ages 11-26 since 2006, yet vaccination rates remain low. Tailored online interventions may be more effective tools to promote behavior change among college students than traditional static interventions. The proposed study is a randomized controlled trial testing the efficacy of the MeFirst tool vs. standard static educational material on increasing HPV vaccination intent and uptake among female university students aged 18-26. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research


Related Conditions & MeSH terms

  • Human Papillomavirus-Related Carcinoma

NCT number NCT01769560
Study type Interventional
Source University of Michigan
Contact
Status Completed
Phase N/A
Start date January 2013
Completion date April 2014

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02379520 - HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA Phase 1
Completed NCT02624349 - Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Phase 4
Recruiting NCT04474821 - HPV Educational Intervention to Increase Acceptance and Completion of Free HPV Vaccination Among Underserved Adults Phase 4
Withdrawn NCT05472220 - Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma Phase 1
Active, not recruiting NCT02568566 - Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants Phase 2
Recruiting NCT05232851 - A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer Phase 1/Phase 2
Not yet recruiting NCT05985681 - Testing RG1-VLP Vaccine to Prevent HPV-related Cancers Phase 1
Completed NCT04189003 - Molecular Signatures of HPV+ ORL Cancers (OROPAP)
Recruiting NCT04927650 - Prevention and Early Detection of Cervical Cancer Through Self-Administered Screening
Recruiting NCT05831540 - Clinical Decision Support Tools to Increase Human Papillomavirus (HPV) Vaccination in Adolescents in Pharmacies N/A
Active, not recruiting NCT04580446 - HYHOPE: De-intensified Hypofractionated Radiation Therapy for HPV-associated Oropharynx Cancer Phase 1
Active, not recruiting NCT03634267 - MRI-Guided Brachytherapy in Treating Participants With HPV-Associated Stage IB2-IVA Cervical or Stage II-IVA Vaginal Cancer Phase 1
Not yet recruiting NCT04142398 - Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men
Completed NCT04880837 - Human Papillomavirus Education Programs N/A